Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) partnered with Nanjing Vazyme Biotech (SHA:688105) in a cooperation agreement to set up a biopharmaceutical joint venture, according to a Shanghai bourse filing on Saturday.
The venture will set up production lines that will produce 10 tons of active pharmaceutical ingredients every year.
Sinopep-Allsino will own 51% of the venture, and Vazyme Biotech will hold 49%.
Sinopep-Allsino's shares closed 10% higher, while Vazyme Biotech's shares closed over 5% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.